Drugs / OLN324
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07484074 | Feb → Oct 2025 | diabetic macular edema, wet macular degeneration | Ollin Biosciences, Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07816289 | Oct 2026 → Dec 2028 expected | wet macular degeneration | Ollin Biosciences, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07842016 | Oct 2026 → Dec 2028 expected | diabetic macular edema | Ollin Biosciences, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07841899 | Oct 2026 → Dec 2028 expected | diabetic macular edema | Ollin Biosciences, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07816315 | Oct 2026 → Dec 2028 expected | wet macular degeneration | Ollin Biosciences, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-09-24 | Ollin Biosciences, Inc. | Results Ollin Biosciences Announces Presentations and Symposium at EURETINA 2026 ollin.bio ↗
In the recently completed head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), OLN324 demonstrated meaningfully faster and greater anatomic outcomes in both DME and wAMD versus faricimab as well as numerically greater vision gains. |
| 2026-03-31 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema innoventbio.com ↗
Final results released include favorable durability data for OLN324 compared to faricimab and new anatomic data showing faster, greater, and more durable control of wAMD pigment epithelial detachments (PEDs) with OLN324. |
| 2026-03-30 | Ollin Biosciences, Inc. | Results Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema ollin.bio ↗
Final results released today include favorable durability data for OLN324 compared to faricimab and new anatomic data showing faster, greater, and more durable control of wAMD pigment epithelial detachments (PEDs). |
| 2026-01-09 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration innoventbio.com ↗
Additionally, nearly 90% of OLN324 4mg treated patients achieved absence of DME at Week 12, defined as CST < 325 µm, as compared to 57% of faricimab patients. |
| 2026-01-08 | Ollin Biosciences, Inc. | Results Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration ollin.bio ↗
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study comparing OLN324, a next-generation VEGF/Ang2 bispecific antibody, to faricimab (Vabysmo®), in over 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD). |
All press releases naming this drug 10 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OLN324 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07816289 ↗ |
| Route | Intravitreal | “Intravitreal Injection” NCT07484074 ↗ |